#METABOLOMICS WORKBENCH RMbeach1053_20221121_093934 DATATRACK_ID:3589 STUDY_ID:ST002354 ANALYSIS_ID:AN003844 PROJECT_ID:PR001511
VERSION             	1
CREATED_ON             	November 22, 2022, 5:53 am
#PROJECT
PR:PROJECT_TITLE                 	Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes.
PR:PROJECT_SUMMARY               	Comprehensive analysis of the lipidomic changes resulting from feeding with a
PR:PROJECT_SUMMARY               	over EPA analogue alone, and in combination with the NSAID naproxen.
PR:INSTITUTE                     	UConn Health
PR:DEPARTMENT                    	Center for Molecular Oncology
PR:LABORATORY                    	Rosenberg Laboratory
PR:LAST_NAME                     	Beach
PR:FIRST_NAME                    	Ryan
PR:ADDRESS                       	263 Farmington Avenue, Farmington, Connecticut, 06030, USA
PR:EMAIL                         	rbeach@uchc.edu
PR:PHONE                         	860-679-8703
PR:FUNDING_SOURCE                	NCI PREVENT funding
#STUDY
ST:STUDY_TITLE                   	Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes.
ST:STUDY_SUMMARY                 	Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in
ST:STUDY_SUMMARY                 	the United States. Patients with the genetic disorder Familial Adenomatous
ST:STUDY_SUMMARY                 	Polyposis (FAP) develop hundreds to thousands of polyps that unless removed by
ST:STUDY_SUMMARY                 	prophylactic colectomy will progress to CRC at an early age. Non-steroidal
ST:STUDY_SUMMARY                 	anti-inflammatory drugs (NSAIDs) and -3 marine polyunsaturated fatty acids
ST:STUDY_SUMMARY                 	(PUFA), such as eicosapentaenoic acid (EPA), have been evaluated for their
ST:STUDY_SUMMARY                 	chemopreventive potential in delaying the onset of CRC in high-risk patients. In
ST:STUDY_SUMMARY                 	this study, we determined whether the NSAID, naproxen, alone or in combination
ST:STUDY_SUMMARY                 	with a chemically-stable form of EPA (TP-252), affects tumor formation in the
ST:STUDY_SUMMARY                 	ApcPirc rat model. When compared to control diet, animals fed naproxen or HD
ST:STUDY_SUMMARY                 	TP-252 had 66%, and 82% fewer tumors respectively. However, when fed a
ST:STUDY_SUMMARY                 	combination of naproxen and HD TP-252, animals exhibited a 95% reduction in
ST:STUDY_SUMMARY                 	tumor formation and a 98% reduction in tumor volume, respectively. To elucidate
ST:STUDY_SUMMARY                 	potential mechanisms of tumor protection, a comprehensive, targeted lipidomic
ST:STUDY_SUMMARY                 	analysis was performed on colonic mucosa to determine changes in eicosanoid
ST:STUDY_SUMMARY                 	metabolism. Animals receiving TP-252 alone or in combination with naproxen had
ST:STUDY_SUMMARY                 	significantly reduced mucosal levels of pro-inflammatory -6 eicosanoids
ST:STUDY_SUMMARY                 	(PGE2, 5-HETE, and 14,15-DiHETrE), along with a simultaneous increase in
ST:STUDY_SUMMARY                 	anti-inflammatory EPA-derived -3 eicosanoids. Our colonic mucosal lipidomic
ST:STUDY_SUMMARY                 	analysis also uncovered several potential pharmacodynamic (PD) lipid biomarkers,
ST:STUDY_SUMMARY                 	including resolvin E2, 9-HEPE, 12-HEPE and 18-HEPE, that were increased in both
ST:STUDY_SUMMARY                 	the tissue and plasma of rats receiving TP-252 and were significantly correlated
ST:STUDY_SUMMARY                 	with tumor protection. Further studies with this drug combination should be
ST:STUDY_SUMMARY                 	focused on dose optimization and the role of EPA-derived lipid mediators in CRC
ST:STUDY_SUMMARY                 	initiation and progression.
ST:INSTITUTE                     	UConn Health
ST:LAST_NAME                     	Beach
ST:FIRST_NAME                    	Ryan
ST:ADDRESS                       	263 Farmington Avenue, Farmington CT 06030
ST:EMAIL                         	rbeach@uchc.edu
ST:PHONE                         	860-679-8703
#SUBJECT
SU:SUBJECT_TYPE                  	Mammal
SU:SUBJECT_SPECIES               	Rattus norvegicus
SU:TAXONOMY_ID                   	10116
SU:AGE_OR_AGE_RANGE              	26 weeks of age
SU:WEIGHT_OR_WEIGHT_RANGE        	320-460 grams
SU:GENDER                        	Male
SU:ANIMAL_ANIMAL_SUPPLIER        	RRRC (University of Missouri)
SU:ANIMAL_HOUSING                	Center for Comparative Medicine UConn
SU:ANIMAL_FEED                   	Modified AIN-93G diet from Research Diets
SU:ANIMAL_WATER                  	ab libitum
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data
SUBJECT_SAMPLE_FACTORS           	2440	TFA-T1	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T1.wiff
SUBJECT_SAMPLE_FACTORS           	2443	TFA-T2	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T2.wiff
SUBJECT_SAMPLE_FACTORS           	2538	TFA-T3	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T3.wiff
SUBJECT_SAMPLE_FACTORS           	2547	TFA-T4	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T4.wiff
SUBJECT_SAMPLE_FACTORS           	3181	TFA-T5	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T5.wiff
SUBJECT_SAMPLE_FACTORS           	3183	TFA-T6	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T6.wiff
SUBJECT_SAMPLE_FACTORS           	2444	TFA-T7	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T7.wiff
SUBJECT_SAMPLE_FACTORS           	2445	TFA-T8	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T8.wiff
SUBJECT_SAMPLE_FACTORS           	2446	TFA-T9	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T9.wiff
SUBJECT_SAMPLE_FACTORS           	2336	TFA-T10	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T10.wiff
SUBJECT_SAMPLE_FACTORS           	2850	TFA-T11	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T11.wiff
SUBJECT_SAMPLE_FACTORS           	2853	TFA-T12	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T12.wiff
SUBJECT_SAMPLE_FACTORS           	2853	TFA-T13	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T13.wiff
SUBJECT_SAMPLE_FACTORS           	3099	TFA-T14	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T14.wiff
SUBJECT_SAMPLE_FACTORS           	2448	TFA-T15	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T15.wiff
SUBJECT_SAMPLE_FACTORS           	2449	TFA-T16	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T16.wiff
SUBJECT_SAMPLE_FACTORS           	2450	TFA-T17	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T17.wiff
SUBJECT_SAMPLE_FACTORS           	2901	TFA-T18	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T18.wiff
SUBJECT_SAMPLE_FACTORS           	2903	TFA-T19	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T19.wiff
SUBJECT_SAMPLE_FACTORS           	3020	TFA-T20	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T20.wiff
SUBJECT_SAMPLE_FACTORS           	3021	TFA-T21	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T21.wiff
SUBJECT_SAMPLE_FACTORS           	2451	TFA-T22	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T22.wiff
SUBJECT_SAMPLE_FACTORS           	2453	TFA-T23	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T23.wiff
SUBJECT_SAMPLE_FACTORS           	2454	TFA-T24	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T24.wiff
SUBJECT_SAMPLE_FACTORS           	2884	TFA-T25	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T25.wiff
SUBJECT_SAMPLE_FACTORS           	2885	TFA-T26	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T26.wiff
SUBJECT_SAMPLE_FACTORS           	2271	TFA-T27	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T27.wiff
SUBJECT_SAMPLE_FACTORS           	2282	TFA-T28	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T28.wiff
SUBJECT_SAMPLE_FACTORS           	2344	TFA-T29	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T29.wiff
SUBJECT_SAMPLE_FACTORS           	2458	TFA-T30	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T30.wiff
SUBJECT_SAMPLE_FACTORS           	2460	TFA-T31	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T31.wiff
SUBJECT_SAMPLE_FACTORS           	2463	TFA-T32	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T32.wiff
SUBJECT_SAMPLE_FACTORS           	2878	TFA-T33	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T33.wiff
SUBJECT_SAMPLE_FACTORS           	2879	TFA-T34	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T34.wiff
SUBJECT_SAMPLE_FACTORS           	2883	TFA-T35	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T35.wiff
SUBJECT_SAMPLE_FACTORS           	2386	TFA-T36	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T36.wiff
SUBJECT_SAMPLE_FACTORS           	2743	TFA-T37	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T37.wiff
SUBJECT_SAMPLE_FACTORS           	2747	TFA-T38	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T38.wiff
SUBJECT_SAMPLE_FACTORS           	2899	TFA-T39	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T39.wiff
SUBJECT_SAMPLE_FACTORS           	2900	TFA-T40	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T40.wiff
SUBJECT_SAMPLE_FACTORS           	3029	TFA-T41	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T41.wiff
SUBJECT_SAMPLE_FACTORS           	3030	TFA-T42	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T42.wiff
SUBJECT_SAMPLE_FACTORS           	2738	TFA-T43	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T43.wiff
SUBJECT_SAMPLE_FACTORS           	2741	TFA-T44	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T44.wiff
SUBJECT_SAMPLE_FACTORS           	2847	TFA-T45	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T45.wiff
SUBJECT_SAMPLE_FACTORS           	2852	TFA-T46	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T46.wiff
SUBJECT_SAMPLE_FACTORS           	2854	TFA-T47	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T47.wiff
SUBJECT_SAMPLE_FACTORS           	3024	TFA-T48	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T48.wiff
SUBJECT_SAMPLE_FACTORS           	2385	TFA-T49	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T49.wiff
SUBJECT_SAMPLE_FACTORS           	3102	TFA-T50	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T50.wiff
SUBJECT_SAMPLE_FACTORS           	3104	TFA-T51	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T51.wiff
SUBJECT_SAMPLE_FACTORS           	2744	TFA-T52	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T52.wiff
SUBJECT_SAMPLE_FACTORS           	2745	TFA-T53	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T53.wiff
SUBJECT_SAMPLE_FACTORS           	2844	TFA-T54	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T54.wiff
SUBJECT_SAMPLE_FACTORS           	2845	TFA-T55	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T55.wiff
SUBJECT_SAMPLE_FACTORS           	2846	TFA-T56	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T56.wiff
SUBJECT_SAMPLE_FACTORS           	2440	EicoT1	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT1.wiff
SUBJECT_SAMPLE_FACTORS           	2443	EicoT2	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT2.wiff
SUBJECT_SAMPLE_FACTORS           	2538	EicoT3	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT3.wiff
SUBJECT_SAMPLE_FACTORS           	2547	EicoT4	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT4.wiff
SUBJECT_SAMPLE_FACTORS           	3181	EicoT5	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT5.wiff
SUBJECT_SAMPLE_FACTORS           	3183	EicoT6	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT6.wiff
SUBJECT_SAMPLE_FACTORS           	2444	EicoT7	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT7.wiff
SUBJECT_SAMPLE_FACTORS           	2445	EicoT8	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT8.wiff
SUBJECT_SAMPLE_FACTORS           	2446	EicoT9	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT9.wiff
SUBJECT_SAMPLE_FACTORS           	2336	EicoT10	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT10.wiff
SUBJECT_SAMPLE_FACTORS           	2850	EicoT11	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT11.wiff
SUBJECT_SAMPLE_FACTORS           	2853	EicoT12	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT12.wiff
SUBJECT_SAMPLE_FACTORS           	2853	EicoT13	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT13.wiff
SUBJECT_SAMPLE_FACTORS           	3099	EicoT14	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT14.wiff
SUBJECT_SAMPLE_FACTORS           	2448	EicoT15	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT15.wiff
SUBJECT_SAMPLE_FACTORS           	2449	EicoT16	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT16.wiff
SUBJECT_SAMPLE_FACTORS           	2450	EicoT17	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT17.wiff
SUBJECT_SAMPLE_FACTORS           	2901	EicoT18	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT18.wiff
SUBJECT_SAMPLE_FACTORS           	2903	EicoT19	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT19.wiff
SUBJECT_SAMPLE_FACTORS           	3020	EicoT20	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT20.wiff
SUBJECT_SAMPLE_FACTORS           	3021	EicoT21	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT21.wiff
SUBJECT_SAMPLE_FACTORS           	2451	EicoT22	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT22.wiff
SUBJECT_SAMPLE_FACTORS           	2453	EicoT23	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT23.wiff
SUBJECT_SAMPLE_FACTORS           	2454	EicoT24	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT24.wiff
SUBJECT_SAMPLE_FACTORS           	2884	EicoT25	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT25.wiff
SUBJECT_SAMPLE_FACTORS           	2885	EicoT26	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT26.wiff
SUBJECT_SAMPLE_FACTORS           	2271	EicoT27	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT27.wiff
SUBJECT_SAMPLE_FACTORS           	2282	EicoT28	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT28.wiff
SUBJECT_SAMPLE_FACTORS           	2344	EicoT29	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT29.wiff
SUBJECT_SAMPLE_FACTORS           	2458	EicoT30	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT30.wiff
SUBJECT_SAMPLE_FACTORS           	2460	EicoT31	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT31.wiff
SUBJECT_SAMPLE_FACTORS           	2463	EicoT32	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT32.wiff
SUBJECT_SAMPLE_FACTORS           	2878	EicoT33	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT33.wiff
SUBJECT_SAMPLE_FACTORS           	2879	EicoT34	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT34.wiff
SUBJECT_SAMPLE_FACTORS           	2883	EicoT35	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT35.wiff
SUBJECT_SAMPLE_FACTORS           	2386	EicoT36	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT36.wiff
SUBJECT_SAMPLE_FACTORS           	2743	EicoT37	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT37.wiff
SUBJECT_SAMPLE_FACTORS           	2747	EicoT38	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT38.wiff
SUBJECT_SAMPLE_FACTORS           	2899	EicoT39	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT39.wiff
SUBJECT_SAMPLE_FACTORS           	2900	EicoT40	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT40.wiff
SUBJECT_SAMPLE_FACTORS           	3029	EicoT41	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT41.wiff
SUBJECT_SAMPLE_FACTORS           	3030	EicoT42	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT42.wiff
SUBJECT_SAMPLE_FACTORS           	2738	EicoT43	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT43.wiff
SUBJECT_SAMPLE_FACTORS           	2741	EicoT44	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT44.wiff
SUBJECT_SAMPLE_FACTORS           	2847	EicoT45	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT45.wiff
SUBJECT_SAMPLE_FACTORS           	2852	EicoT46	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT46.wiff
SUBJECT_SAMPLE_FACTORS           	2854	EicoT47	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT47.wiff
SUBJECT_SAMPLE_FACTORS           	3024	EicoT48	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT48.wiff
SUBJECT_SAMPLE_FACTORS           	2385	EicoT49	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT49.wiff
SUBJECT_SAMPLE_FACTORS           	3102	EicoT50	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT50.wiff
SUBJECT_SAMPLE_FACTORS           	3104	EicoT51	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT51.wiff
SUBJECT_SAMPLE_FACTORS           	2744	EicoT52	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT52.wiff
SUBJECT_SAMPLE_FACTORS           	2745	EicoT53	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT53.wiff
SUBJECT_SAMPLE_FACTORS           	2844	EicoT54	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT54.wiff
SUBJECT_SAMPLE_FACTORS           	2845	EicoT55	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT55.wiff
SUBJECT_SAMPLE_FACTORS           	2846	EicoT56	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT56.wiff
SUBJECT_SAMPLE_FACTORS           	2538	TFA-P1	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P1.wiff
SUBJECT_SAMPLE_FACTORS           	2547	TFA-P2	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P2.wiff
SUBJECT_SAMPLE_FACTORS           	2442	TFA-P3	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P3.wiff
SUBJECT_SAMPLE_FACTORS           	2440	TFA-P4	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P4.wiff
SUBJECT_SAMPLE_FACTORS           	3183	TFA-P5	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P5.wiff
SUBJECT_SAMPLE_FACTORS           	3181	TFA-P6	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P6.wiff
SUBJECT_SAMPLE_FACTORS           	3190	TFA-P7	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P7.wiff
SUBJECT_SAMPLE_FACTORS           	2165	TFA-P8	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P8.wiff
SUBJECT_SAMPLE_FACTORS           	2167	TFA-P9	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P9.wiff
SUBJECT_SAMPLE_FACTORS           	2168	TFA-P10	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P10.wiff
SUBJECT_SAMPLE_FACTORS           	2333	TFA-P11	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P11.wiff
SUBJECT_SAMPLE_FACTORS           	2444	TFA-P12	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P12.wiff
SUBJECT_SAMPLE_FACTORS           	2445	TFA-P13	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P13.wiff
SUBJECT_SAMPLE_FACTORS           	2853	TFA-P14	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P14.wiff
SUBJECT_SAMPLE_FACTORS           	2264	TFA-P15	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P15.wiff
SUBJECT_SAMPLE_FACTORS           	2267	TFA-P16	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P16.wiff
SUBJECT_SAMPLE_FACTORS           	2265	TFA-P17	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P17.wiff
SUBJECT_SAMPLE_FACTORS           	2448	TFA-P18	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P18.wiff
SUBJECT_SAMPLE_FACTORS           	2449	TFA-P19	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P19.wiff
SUBJECT_SAMPLE_FACTORS           	2450	TFA-P20	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P20.wiff
SUBJECT_SAMPLE_FACTORS           	3020	TFA-P21	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P21.wiff
SUBJECT_SAMPLE_FACTORS           	2170	TFA-P22	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P22.wiff
SUBJECT_SAMPLE_FACTORS           	2169	TFA-P23	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P23.wiff
SUBJECT_SAMPLE_FACTORS           	2271	TFA-P24	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P24.wiff
SUBJECT_SAMPLE_FACTORS           	2451	TFA-P25	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P25.wiff
SUBJECT_SAMPLE_FACTORS           	2453	TFA-P26	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P26.wiff
SUBJECT_SAMPLE_FACTORS           	2284	TFA-P27	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P27.wiff
SUBJECT_SAMPLE_FACTORS           	2282	TFA-P28	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P28.wiff
SUBJECT_SAMPLE_FACTORS           	2344	TFA-P29	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P29.wiff
SUBJECT_SAMPLE_FACTORS           	2458	TFA-P30	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P30.wiff
SUBJECT_SAMPLE_FACTORS           	2352	TFA-P31	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P31.wiff
SUBJECT_SAMPLE_FACTORS           	2460	TFA-P32	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P32.wiff
SUBJECT_SAMPLE_FACTORS           	2879	TFA-P33	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P33.wiff
SUBJECT_SAMPLE_FACTORS           	2883	TFA-P34	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P34.wiff
SUBJECT_SAMPLE_FACTORS           	2463	TFA-P35	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P35.wiff
SUBJECT_SAMPLE_FACTORS           	2171	TFA-P36	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P36.wiff
SUBJECT_SAMPLE_FACTORS           	2174	TFA-P37	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P37.wiff
SUBJECT_SAMPLE_FACTORS           	2175	TFA-P38	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P38.wiff
SUBJECT_SAMPLE_FACTORS           	2386	TFA-P39	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P39.wiff
SUBJECT_SAMPLE_FACTORS           	2387	TFA-P40	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P40.wiff
SUBJECT_SAMPLE_FACTORS           	2900	TFA-P41	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P41.wiff
SUBJECT_SAMPLE_FACTORS           	2743	TFA-P42	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P42.wiff
SUBJECT_SAMPLE_FACTORS           	2385	TFA-P43	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P43.wiff
SUBJECT_SAMPLE_FACTORS           	2394	TFA-P44	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P44.wiff
SUBJECT_SAMPLE_FACTORS           	2398	TFA-P45	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P45.wiff
SUBJECT_SAMPLE_FACTORS           	2738	TFA-P46	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P46.wiff
SUBJECT_SAMPLE_FACTORS           	2741	TFA-P47	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P47.wiff
SUBJECT_SAMPLE_FACTORS           	2847	TFA-P48	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P48.wiff
SUBJECT_SAMPLE_FACTORS           	2852	TFA-P49	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P49.wiff
SUBJECT_SAMPLE_FACTORS           	2177	TFA-P50	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P50.wiff
SUBJECT_SAMPLE_FACTORS           	2180	TFA-P51	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P51.wiff
SUBJECT_SAMPLE_FACTORS           	2384	TFA-P52	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P52.wiff
SUBJECT_SAMPLE_FACTORS           	2389	TFA-P53	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P53.wiff
SUBJECT_SAMPLE_FACTORS           	2391	TFA-P54	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P54.wiff
SUBJECT_SAMPLE_FACTORS           	2744	TFA-P55	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P55.wiff
SUBJECT_SAMPLE_FACTORS           	2745	TFA-P56	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P56.wiff
SUBJECT_SAMPLE_FACTORS           	2538	EicoP1	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP1.wiff
SUBJECT_SAMPLE_FACTORS           	2547	EicoP2	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP2.wiff
SUBJECT_SAMPLE_FACTORS           	2442	EicoP3	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP3.wiff
SUBJECT_SAMPLE_FACTORS           	2440	EicoP4	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP4.wiff
SUBJECT_SAMPLE_FACTORS           	3183	EicoP5	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP5.wiff
SUBJECT_SAMPLE_FACTORS           	3181	EicoP6	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP6.wiff
SUBJECT_SAMPLE_FACTORS           	3190	EicoP7	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP7.wiff
SUBJECT_SAMPLE_FACTORS           	2165	EicoP8	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP8.wiff
SUBJECT_SAMPLE_FACTORS           	2167	EicoP9	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP9.wiff
SUBJECT_SAMPLE_FACTORS           	2168	EicoP10	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP10.wiff
SUBJECT_SAMPLE_FACTORS           	2333	EicoP11	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP11.wiff
SUBJECT_SAMPLE_FACTORS           	2444	EicoP12	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP12.wiff
SUBJECT_SAMPLE_FACTORS           	2445	EicoP13	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP13.wiff
SUBJECT_SAMPLE_FACTORS           	2853	EicoP14	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP14.wiff
SUBJECT_SAMPLE_FACTORS           	2264	EicoP15	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP15.wiff
SUBJECT_SAMPLE_FACTORS           	2267	EicoP16	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP16.wiff
SUBJECT_SAMPLE_FACTORS           	2265	EicoP17	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP17.wiff
SUBJECT_SAMPLE_FACTORS           	2448	EicoP18	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP18.wiff
SUBJECT_SAMPLE_FACTORS           	2449	EicoP19	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP19.wiff
SUBJECT_SAMPLE_FACTORS           	2450	EicoP20	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP20.wiff
SUBJECT_SAMPLE_FACTORS           	3020	EicoP21	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP21.wiff
SUBJECT_SAMPLE_FACTORS           	2170	EicoP22	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP22.wiff
SUBJECT_SAMPLE_FACTORS           	2169	EicoP23	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP23.wiff
SUBJECT_SAMPLE_FACTORS           	2271	EicoP24	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP24.wiff
SUBJECT_SAMPLE_FACTORS           	2451	EicoP25	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP25.wiff
SUBJECT_SAMPLE_FACTORS           	2453	EicoP26	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP26.wiff
SUBJECT_SAMPLE_FACTORS           	2284	EicoP27	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP27.wiff
SUBJECT_SAMPLE_FACTORS           	2282	EicoP28	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP28.wiff
SUBJECT_SAMPLE_FACTORS           	2344	EicoP29	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP29.wiff
SUBJECT_SAMPLE_FACTORS           	2458	EicoP30	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP30.wiff
SUBJECT_SAMPLE_FACTORS           	2352	EicoP31	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP31.wiff
SUBJECT_SAMPLE_FACTORS           	2460	EicoP32	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP32.wiff
SUBJECT_SAMPLE_FACTORS           	2879	EicoP33	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP33.wiff
SUBJECT_SAMPLE_FACTORS           	2883	EicoP34	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP34.wiff
SUBJECT_SAMPLE_FACTORS           	2463	EicoP35	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP35.wiff
SUBJECT_SAMPLE_FACTORS           	2171	EicoP36	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP36.wiff
SUBJECT_SAMPLE_FACTORS           	2174	EicoP37	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP37.wiff
SUBJECT_SAMPLE_FACTORS           	2175	EicoP38	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP38.wiff
SUBJECT_SAMPLE_FACTORS           	2386	EicoP39	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP39.wiff
SUBJECT_SAMPLE_FACTORS           	2387	EicoP40	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP40.wiff
SUBJECT_SAMPLE_FACTORS           	2900	EicoP41	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP41.wiff
SUBJECT_SAMPLE_FACTORS           	2743	EicoP42	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP42.wiff
SUBJECT_SAMPLE_FACTORS           	2385	EicoP43	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP43.wiff
SUBJECT_SAMPLE_FACTORS           	2394	EicoP44	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP44.wiff
SUBJECT_SAMPLE_FACTORS           	2398	EicoP45	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP45.wiff
SUBJECT_SAMPLE_FACTORS           	2738	EicoP46	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP46.wiff
SUBJECT_SAMPLE_FACTORS           	2741	EicoP47	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP47.wiff
SUBJECT_SAMPLE_FACTORS           	2847	EicoP48	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP48.wiff
SUBJECT_SAMPLE_FACTORS           	2852	EicoP49	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP49.wiff
SUBJECT_SAMPLE_FACTORS           	2177	EicoP50	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP50.wiff
SUBJECT_SAMPLE_FACTORS           	2180	EicoP51	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP51.wiff
SUBJECT_SAMPLE_FACTORS           	2384	EicoP52	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP52.wiff
SUBJECT_SAMPLE_FACTORS           	2389	EicoP53	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP53.wiff
SUBJECT_SAMPLE_FACTORS           	2391	EicoP54	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP54.wiff
SUBJECT_SAMPLE_FACTORS           	2744	EicoP55	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP55.wiff
SUBJECT_SAMPLE_FACTORS           	2745	EicoP56	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP56.wiff
#COLLECTION
CO:COLLECTION_SUMMARY            	Animals were sacrificed by CO2 narcosis, and large intestines were excised,
CO:COLLECTION_SUMMARY            	washed with ice-cold PBS, and laid flat on filter paper. Tumor-adjacent
CO:COLLECTION_SUMMARY            	full-thickness colon segments were flash-frozen in liquid Nitrogen and stored at
CO:COLLECTION_SUMMARY            	-80C until analysis. Blood was collected via cardiac puncture and put in lithium
CO:COLLECTION_SUMMARY            	heparin tubes on ice. Samples were centrifuged at 2,000 g for 20 minutes, and
CO:COLLECTION_SUMMARY            	supernatant (plasma) was collected and stored at -80C until analysis.
CO:SAMPLE_TYPE                   	Blood (Plasma) and Large Intestine
#TREATMENT
TR:TREATMENT_SUMMARY             	Rats were fed two doses of TP-252 equivalent to consuming 1.3 and 2.6 g/kg/day
TR:TREATMENT_SUMMARY             	for LD TP-252 and HD TP-252, respectively. Alternatively, rats were also fed a
TR:TREATMENT_SUMMARY             	diet containing 2% EPA-FFA in their diet (equivalent to 1.14 g/kg/day of EPA).
TR:TREATMENT_SUMMARY             	In groups receiving naproxen, the dose of naproxen was 11.4 mg/kg/day, or
TR:TREATMENT_SUMMARY             	roughly 4 mg/rat/day. These treatment groups were carried out for the 20 weeks,
TR:TREATMENT_SUMMARY             	and then animals were sacrificed and tissue collected and analyzed.
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	Samples (0.85 ml) were spiked with 5 ng each (in 150 μl methanol) of
SP:SAMPLEPREP_SUMMARY            	15(S)-HETE-d8,14(15)-EpETrE-d11, Resolvin D2-d5, Leukotriene B4-d4, and
SP:SAMPLEPREP_SUMMARY            	Prostaglandin E1-d4 as internal standards for recovery and quantitation and
SP:SAMPLEPREP_SUMMARY            	mixed thoroughly. The samples were then extracted for PUFA metabolites using C18
SP:SAMPLEPREP_SUMMARY            	extraction columns as described earlier [1-4]. Briefly, the internal standard
SP:SAMPLEPREP_SUMMARY            	spiked samples were applied to conditioned C18 cartridges, washed with 15%
SP:SAMPLEPREP_SUMMARY            	methanol in water followed by hexane and dried under vacuum. The cartridges were
SP:SAMPLEPREP_SUMMARY            	eluted with 0.5 ml methanol. The eluate was dried under a gentle stream of
SP:SAMPLEPREP_SUMMARY            	nitrogen. The residue was redissolved in 50 μl methanol-25 mM aqueous ammonium
SP:SAMPLEPREP_SUMMARY            	acetate (1:1) and subjected to LC-MS analysis.
SP:SAMPLEPREP_PROTOCOL_FILENAME  	Methods of Eicosanoid Detection.pdf
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_SUMMARY        	HPLC was performed on a Prominence XR system (Shimadzu) using Luna C18 (3μ,
CH:CHROMATOGRAPHY_SUMMARY        	2.1x150 mm) column. The mobile phase consisted of a gradient between A:
CH:CHROMATOGRAPHY_SUMMARY        	methanol-water-acetonitrile (10:85:5 v/v) and B: methanol-water-acetonitrile
CH:CHROMATOGRAPHY_SUMMARY        	(90:5:5 v/v), both containing 0.1% ammonium acetate. The gradient program with
CH:CHROMATOGRAPHY_SUMMARY        	respect to the composition of B was as follows: 0-1 min, 50%; 1-8 min, 50-80%;
CH:CHROMATOGRAPHY_SUMMARY        	8-15 min, 80-95%; and 15-17 min, 95%. The flow rate was 0.2 ml/min. The HPLC
CH:CHROMATOGRAPHY_SUMMARY        	eluate was directly introduced to ESI source of QTRAP5500 mass analyzer
CH:CHROMATOGRAPHY_SUMMARY        	(ABSCIEX) in the negative ion mode with following conditions: Curtain gas: 35
CH:CHROMATOGRAPHY_SUMMARY        	psi, GS1: 35 psi, GS2: 65 psi, Temperature: 600 ˚C, Ion Spray Voltage: -1500 V,
CH:CHROMATOGRAPHY_SUMMARY        	Collision gas: low, Declustering Potential: -60 V, and Entrance Potential: -7 V.
CH:CHROMATOGRAPHY_SUMMARY        	The eluate was monitored by Multiple Reaction Monitoring method to detect unique
CH:CHROMATOGRAPHY_SUMMARY        	molecular ion – daughter ion combinations for each of the lipid mediators
CH:CHROMATOGRAPHY_SUMMARY        	using a scheduled MRM around the expected retention time for each compound.
CH:CHROMATOGRAPHY_SUMMARY        	Optimized Collisional Energies (18 – 35 eV) and Collision Cell Exit Potentials
CH:CHROMATOGRAPHY_SUMMARY        	(7 – 10 V) were used for each MRM transition. Spectra of each peak detected in
CH:CHROMATOGRAPHY_SUMMARY        	the scheduled MRM were recorded using Enhanced Product Ion scan to confirm the
CH:CHROMATOGRAPHY_SUMMARY        	structural identity. The data was collected using Analyst 1.6.2 software and the
CH:CHROMATOGRAPHY_SUMMARY        	MRM transition chromatograms were quantitated by MultiQuant software (both from
CH:CHROMATOGRAPHY_SUMMARY        	ABSCIEX). The internal standard signals in each chromatogram were used for
CH:CHROMATOGRAPHY_SUMMARY        	normalization, recovery, as well as relative quantitation of each analyte.
CH:CHROMATOGRAPHY_TYPE           	None (Direct infusion)
CH:INSTRUMENT_NAME               	Prominence XR
CH:COLUMN_NAME                   	Targa C8, 2x10 mm, 5μ
CH:FLOW_RATE                     	0.25ml/min
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
#MS
MS:INSTRUMENT_NAME               	ABI Sciex 5500 QTrap
MS:INSTRUMENT_TYPE               	QTRAP
MS:MS_TYPE                       	ESI
MS:ION_MODE                      	NEGATIVE
MS:MS_COMMENTS                   	Mass spectra for each detected lipid metabolite were recorded using the enhanced
MS:MS_COMMENTS                   	production feature to verify the identity of the detected peak. Data were
MS:MS_COMMENTS                   	collected and quantified using Analyst 1.6.2 (SCIEX) and MultiQuant (SCIEX)
MS:MS_COMMENTS                   	software, respectively. Correction for recovery efficiencies and relative
MS:MS_COMMENTS                   	quantitation of each analyte were performed using signals from each chromatogram
MS:MS_COMMENTS                   	corresponding to the spiked-in internal standards. Under standardized conditions
MS:MS_COMMENTS                   	of liquid chromatography-mass spectrometry quantitation, the detection limits
MS:MS_COMMENTS                   	for the eicosanoids are 1–2 pg on the column and the limit of quantitation is
MS:MS_COMMENTS                   	5 pg at a signal-to-noise ratio of 3.
#MS_METABOLITE_DATA
MS_METABOLITE_DATA:UNITS	mg/mL
MS_METABOLITE_DATA_START
Samples	TFA-P1	TFA-P2	TFA-P3	TFA-P4	TFA-P5	TFA-P6	TFA-P7	TFA-P8	TFA-P9	TFA-P10	TFA-P11	TFA-P12	TFA-P13	TFA-P14	TFA-P15	TFA-P16	TFA-P17	TFA-P18	TFA-P19	TFA-P20	TFA-P21	TFA-P22	TFA-P23	TFA-P24	TFA-P25	TFA-P26	TFA-P27	TFA-P28	TFA-P29	TFA-P30	TFA-P31	TFA-P32	TFA-P33	TFA-P34	TFA-P35	TFA-P36	TFA-P37	TFA-P38	TFA-P39	TFA-P40	TFA-P41	TFA-P42	TFA-P43	TFA-P44	TFA-P45	TFA-P46	TFA-P47	TFA-P48	TFA-P49	TFA-P50	TFA-P51	TFA-P52	TFA-P53	TFA-P54	TFA-P55	TFA-P56
Factors	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma
Dodecanoic acid	0.111	0.065	0.126	0.198	0.189	0.178	0.197		0.137	0.200	0.196	0.144		0.154		0.100	0.123	0.127	0.387	0.098	0.125		0.048	0.254	0.161	0.191	0.153		0.203	0.301	0.141	0.156	0.244	0.383		0.270	0.202	0.165	0.089	0.340	0.163	0.106	0.221	0.209	0.161	0.224	0.132	0.158	0.150	0.185	0.162	0.235	0.173	0.144	0.185	0.150
Myristic acid	0.535	0.369	0.409	0.414	0.312	0.584	0.554	0.260	0.456	0.291	0.603	0.287	0.310	0.373	0.160	0.223	0.301	0.407	0.407	0.276	0.294	0.141	0.225	0.270	0.209	0.207	0.266	0.126	0.159	0.413	0.233	0.269	0.315	0.434	0.258	0.209	0.301	0.269	0.164	0.211	0.196	0.195	0.276	0.301	0.307	0.283	0.427	0.150	0.261	0.243	0.328	0.249	0.236	0.221	0.277	0.260
Pentadecanoic acid	0.232	0.116	0.138	0.137	0.179	0.150	0.146	0.153	0.158	0.128	0.164	0.114	0.131	0.141	0.060	0.151	0.122	0.152	0.151	0.136	0.149	0.092	0.126	0.149	0.116	0.119	0.149	0.068	0.083	0.167	0.097	0.109	0.112	0.167	0.120	0.151	0.193	0.177	0.103	0.134	0.102	0.089	0.096	0.094	0.155	0.137	0.206	0.076	0.149	0.114	0.143	0.106	0.101	0.088	0.156	0.114
Palmitoleic acid	2.744	1.996	3.041	3.042	1.879	4.657	5.531	1.795	3.313	2.329	4.987	1.905	2.217	3.687	1.275	1.493	2.054	2.008	2.491	1.610	1.591	0.618	1.011	1.412	1.247	1.043	1.148	0.510	0.697	4.278	1.996	1.698	1.676	2.685	1.669	1.119	1.239	1.200	0.809	0.641	1.200	0.996	2.999	2.600	2.958	1.728	3.457	0.990	2.519	1.781	2.346	1.816	1.498	1.428	1.467	1.620
Palmitic acid	2.717	2.194	2.367	3.353	2.401	2.334	2.677	2.266	3.583	2.228	2.579	2.155	2.119	2.420	1.773	2.402	2.628	2.393	2.523	2.523	2.572	2.309	2.337	3.021	2.747	1.596	2.918	1.598	2.129	3.053	2.673	2.784	2.688	2.672	2.572	2.616	2.613	2.550	2.420	1.331	2.493	2.393	2.419	2.442	2.926	2.842	2.447	1.688	2.562	2.609	2.714	2.477	2.344	2.275	2.529	2.522
Heptadecenoic acid	0.079	0.036	0.063	0.066	0.043	0.070	0.071	0.059	0.073	0.050	0.073	0.038	0.041	0.056	0.029	0.038	0.038	0.050	0.057	0.042	0.035	0.020	0.026	0.033	0.028	0.032	0.039	0.017	0.021	0.077	0.035	0.040	0.040	0.062	0.034	0.034	0.044	0.044	0.029	0.027	0.029	0.029	0.050	0.043	0.057	0.041	0.072	0.029	0.055	0.036	0.049	0.038	0.038	0.027	0.041	0.035
Heptadecanoic acid	0.212	0.144	0.152	0.184	0.145	0.149	0.154	0.220	0.205	0.171	0.141	0.162	0.159	0.152	0.115	0.173	0.122	0.134	0.128	0.159	0.147	0.125	0.130	0.151	0.134	0.115	0.155	0.090	0.115	0.152	0.127	0.153	0.124	0.151	0.135	0.145	0.173	0.185	0.172	0.081	0.133	0.151	0.118	0.118	0.134	0.158	0.147	0.123	0.149	0.129	0.159	0.134	0.098	0.121	0.140	0.142
Octadecatetraenoic acid (Stearidonic acid)	0.001	0.000	0.001	0.000	0.001	0.001	0.001	0.001	0.000	0.000	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.000	0.000	0.001	0.001	0.001	0.001	0.000	0.000	0.001	0.000	0.001	0.001	0.001	0.000	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.000	0.000	0.000	0.000	0.001	0.001	0.001	0.000	0.001	0.001	0.000	0.000	0.001	0.001
Linolenic acid (alpha)	0.036	0.015	0.021	0.014	0.026	0.026	0.021	0.018	0.015	0.012	0.021	0.016	0.019	0.022	0.007	0.010	0.008	0.010	0.013	0.011	0.008	0.003	0.004	0.005	0.005	0.006	0.008	0.003	0.003	0.012	0.006	0.008	0.011	0.014	0.008	0.005	0.006	0.007	0.005	0.005	0.004	0.006	0.005	0.004	0.004	0.006	0.010	0.007	0.010	0.005	0.008	0.006	0.005	0.005	0.007	0.008
Linoleic acid	8.339	8.853	10.888	8.818	8.921	9.338	7.120	8.439	9.103	8.229	9.217	8.094	8.360	9.010	6.515	7.186	6.864	7.905	9.032	9.597	7.881	5.263	5.720	6.773	6.178	7.167	7.702	4.679	6.027	9.656	8.094	7.743	8.488	10.758	7.827	7.040	7.145	8.189	5.469	7.458	4.518	6.385	6.089	5.579	6.145	6.578	8.108	8.588	7.988	6.933	8.321	6.498	7.701	5.898	7.951	6.620
Oleic acid	8.572	3.851	6.707	5.640	7.153	7.271	7.229	4.438	5.985	4.394	7.275	4.090	4.558	5.769	2.998	4.468	3.409	4.869	5.827	4.520	3.125	1.822	2.363	2.870	2.554	2.913	3.438	1.742	1.557	6.492	3.098	3.479	4.062	6.036	3.135	2.783	3.844	3.841	2.299	2.616	2.114	2.608	3.932	3.694	4.468	3.366	6.159	3.792	6.302	3.361	4.188	3.596	3.367	2.409	3.091	3.361
Stearic acid	2.670	2.537	2.799	2.855	2.462	2.534	2.746	2.585	2.750	2.810	2.757	2.498	2.504	2.745	1.939	2.491	2.643	2.563	2.679	2.568	2.267	2.405	2.577	2.571	2.453	2.261	2.566	2.069	2.430	2.839	2.519	2.543	2.502	2.701	2.700	2.597	2.724	2.532	2.267	2.852	2.388	2.159	2.543	2.975	2.711	2.673	2.701	2.151	2.718	2.759	2.631	2.633	2.759	2.367	2.420	2.760
Eicosapentaenoic acid	0.033	0.025	0.034	0.025	0.023	0.045	0.041	0.025	0.026	0.020	0.046	0.029	0.032	0.040	0.256	0.277	0.358	0.378	0.493	0.318	0.288	0.208	0.245	0.305	0.260	0.312	0.410	0.208	0.241	0.401	0.354	0.281	0.359	0.469	0.279	0.334	0.471	0.514	0.283	0.309	0.315	0.353	0.307	0.340	0.281	0.363	0.664	0.279	0.381	0.311	0.414	0.321	0.098	0.227	0.306	0.367
Arachidonic acid	1.133	0.908	1.079	1.059	1.304	1.198	1.146	0.693	1.139	0.829	1.214	0.842	0.980	0.946	0.281	0.349	0.333	0.311	0.410	0.281	0.250	0.094	0.111	0.093	0.087	0.105	0.111	0.068	0.144	0.333	0.238	0.242	0.349	0.423	0.299	0.129	0.123	0.136	0.090	0.096	0.096	0.114	0.250	0.265	0.291	0.246	0.501	0.314	0.409	0.235	0.274	0.250	0.231	0.184	0.221	0.273
Dihomo-g-linolenic acid	0.076	0.061	0.069	0.076	0.092	0.081	0.076	0.048	0.078	0.060	0.082	0.059	0.065	0.063	0.019	0.023	0.021	0.020	0.027	0.019	0.017	0.007	0.006	0.006	0.006	0.006	0.008	0.004	0.009	0.025	0.016	0.014	0.024	0.027	0.022	0.009	0.007	0.009	0.006	0.006	0.005	0.007	0.017	0.016	0.021	0.014	0.035	0.020	0.027	0.016	0.015	0.017	0.014	0.011	0.014	0.018
Mead acid	0.025	0.012	0.024	0.022	0.016	0.020	0.020	0.012	0.025	0.013	0.038	0.014	0.020	0.021	0.010	0.010	0.010	0.013	0.013	0.010	0.008	0.003	0.003	0.004	0.004	0.004	0.003	0.003	0.004	0.014	0.009	0.007	0.011	0.014	0.009	0.005	0.004	0.005	0.004	0.003	0.003	0.005	0.012	0.016	0.015	0.009	0.019	0.013	0.020	0.010	0.011	0.008	0.002	0.007	0.007	0.009
Eicosadienoic acid	0.204	0.132	0.193	0.122	0.128	0.208	0.137	0.126	0.133	0.120	0.156	0.155	0.176	0.177	0.085	0.083	0.047	0.084	0.077	0.103	0.057	0.029	0.037	0.035	0.034	0.054	0.039	0.034	0.040	0.076	0.055	0.057	0.082	0.094	0.060	0.040	0.045	0.046	0.043	0.042	0.024	0.042	0.064	0.064	0.059	0.044	0.070	0.075	0.071	0.056	0.063	0.051	0.025	0.045	0.065	0.051
Eicosenoic acid	0.410	0.174	0.270	0.163	0.357	0.336	0.229	0.236	0.165	0.132	0.178	0.174	0.200	0.219	0.130	0.205	0.084	0.150	0.151	0.213	0.085	0.065	0.071	0.084	0.074	0.120	0.095	0.045	0.056	0.188	0.097	0.097	0.110	0.214	0.081	0.080	0.146	0.183	0.117	0.091	0.061	0.125	0.087	0.066	0.084	0.110	0.234	0.209	0.191	0.095	0.129	0.102	0.169	0.081	0.125	0.081
Arachidic acid	0.155	0.084	0.076	0.042	0.072	0.100	0.078	0.086	0.039	0.061	0.078	0.069	0.085	0.086	0.109	0.080	0.077	0.068	0.068	0.102	0.073	0.068	0.067	0.067	0.068	0.134	0.087	0.085	0.064	0.075	0.070	0.070	0.071	0.076	0.069	0.066	0.084	0.099	0.130	0.135	0.052	0.095	0.049	0.058	0.052	0.051	0.076	0.130	0.055	0.060	0.064	0.064	0.079	0.047	0.071	0.061
Docosahexaenoic acid	0.503	0.318	0.432	0.400	0.597	0.556	0.484	0.226	0.400	0.289	0.366	0.259	0.276	0.299	0.202	0.256	0.249	0.237	0.292	0.229	0.184	0.079	0.090	0.090	0.091	0.115	0.100	0.073	0.099	0.196	0.178	0.145	0.228	0.241	0.190	0.124	0.126	0.130	0.084	0.109	0.100	0.119	0.264	0.313	0.308	0.218	0.455	0.243	0.387	0.188	0.225	0.161	0.124	0.125	0.164	0.203
Docosapentaenoic acid (n-3)	0.016	0.009	0.015	0.014	0.018	0.017	0.015	0.010	0.013	0.010	0.014	0.011	0.012	0.014	0.037	0.041	0.035	0.046	0.053	0.044	0.031	0.022	0.027	0.029	0.025	0.033	0.038	0.026	0.023	0.043	0.032	0.028	0.044	0.055	0.031	0.032	0.045	0.041	0.030	0.035	0.029	0.032	0.041	0.043	0.043	0.037	0.072	0.044	0.064	0.032	0.044	0.034	0.017	0.025	0.035	0.040
Docosapentaenoic acid (n-6)	0.033	0.030	0.027	0.026	0.028	0.040	0.038	0.018	0.028	0.019	0.031	0.014	0.012	0.019																																										
Docosatetraenoic acid	0.035	0.018	0.025	0.018	0.037	0.031	0.022	0.017	0.018	0.013	0.017	0.017	0.019	0.019	0.002	0.003	0.001	0.002	0.002	0.002	0.001	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.002	0.001	0.001	0.002	0.002	0.001		0.000	0.000	0.000	0.000	0.000	0.000	0.001	0.001	0.001	0.001	0.002	0.001	0.002	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Docosatrienoic acid	0.004	0.003	0.005	0.004	0.003	0.004	0.003	0.003	0.004	0.003	0.003	0.003	0.003	0.003	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.000	0.000	0.000	0.000	0.001	0.000	0.000	0.000	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.000	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Docosadienoic acid	0.002	0.001	0.002	0.001	0.001	0.002	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.000	0.000	0.001	0.001	0.001	0.001	0.000	0.000	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.000	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.000	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Docosenoic acid	0.261	0.205	0.368	0.769	0.161	0.153	0.120	0.191	0.706	0.297	0.184	0.147	0.231	0.282	0.092	0.164	0.559	0.174	0.152	0.256	0.085	0.256	0.119	0.226	0.343	0.109	0.325	0.052	0.249	0.344	0.383	0.440	0.155	0.294	0.254	0.308	0.364	0.505	0.134	0.088	0.250	0.196	0.519	0.202	0.388	0.400	0.471	0.149	0.183	0.326	0.264	0.363	0.422	0.235	0.286	0.404
Docosanoic acid (Behenic acid)	0.838	0.265	0.288	0.328	0.203	0.237	0.202	0.258	0.336	0.233	0.322	0.149	0.212	0.213	0.099	0.236	0.356	0.163	0.146	0.286	0.246	0.218	0.097	0.152	0.234	0.132	0.281	0.060	0.176	0.341	0.320	0.369	0.264	0.302	0.175	0.254	0.276	0.361	0.184	0.058	0.181	0.190	0.214	0.181	0.306	0.204	0.414	0.115	0.202	0.208	0.184	0.198	0.198	0.092	0.237	0.210
Nervonic acid	0.544	0.272	0.346	0.471	0.421	0.283	0.204	0.318	0.356	0.195	0.250	0.197	0.284	0.196	0.119	0.408	0.286	0.147	0.138	0.413	0.158	0.424	0.138	0.223	0.290	0.163	0.302	0.062	0.262	0.330	0.472	0.368	0.202	0.369	0.158	0.327	0.436	0.673	0.271	0.075	0.288	0.273	0.252	0.155	0.296	0.374	0.730	0.235	0.259	0.229	0.239	0.364	0.381	0.181	0.367	0.187
Lignoceric acid	0.654	0.283	0.337	0.349	0.288	0.228	0.229	0.296	0.329	0.292	0.352	0.199	0.258	0.253	0.097	0.360	0.395	0.198	0.178	0.371	0.258	0.394	0.160	0.233	0.342	0.124	0.393	0.072	0.289	0.438	0.460	0.516	0.283	0.423	0.220	0.373	0.452	0.475	0.202	0.082	0.314	0.172	0.320	0.252	0.421	0.222	0.596	0.127	0.299	0.296	0.264	0.287	0.313	0.167	0.390	0.276
Hexacosenoic acid	0.075	0.053	0.074	0.053	0.092	0.043	0.043	0.083	0.041	0.046	0.054	0.045	0.068	0.044	0.018	0.108	0.072	0.029	0.034	0.098	0.036	0.131	0.039	0.074	0.080	0.032	0.087	0.012	0.087	0.095	0.139	0.105	0.047	0.092	0.042	0.085	0.128	0.173	0.056	0.016	0.087	0.050	0.068	0.046	0.082	0.065	0.233	0.037	0.071	0.056	0.067	0.074	0.135	0.058	0.112	0.051
Hexacosanoic acid	0.098	0.049	0.058	0.068	0.063	0.040	0.047	0.055	0.053	0.052	0.062	0.031	0.054	0.042	0.011	0.068	0.062	0.035	0.028	0.076	0.037	0.093	0.031	0.042	0.056	0.015	0.062	0.007	0.051	0.061	0.076	0.099	0.041	0.073	0.039	0.073	0.075	0.069	0.021	0.011	0.060	0.024	0.056	0.043	0.073	0.038	0.100	0.017	0.052	0.064	0.052	0.058	0.069	0.028	0.061	0.045
MS_METABOLITE_DATA_END
#METABOLITES
METABOLITES_START
metabolite_name	KEGG ID	PubChem ID	quantified m/z
Dodecanoic acid	C02679	3893	200
Myristic acid	C06242	11005	228
Pentadecanoic acid	C16537	13849	242
Palmitoleic acid	C08362	445638	254
Palmitic acid	C00249	985	256
Heptadecenoic acid	C16536	5312440	268
Heptadecanoic acid		10465	270
Octadecatetraenoic acid (Stearidonic acid)	C16300	5312508	276
Linolenic acid (alpha)	C06427	8662	278
Linoleic acid	C01595	5280450	280
Oleic acid	C00712	3978	282
Stearic acid	C01530	4692	284
Eicosapentaenoic acid	C06428	446284	302
Arachidonic acid	C00219	444899	304
Dihomo-g-linolenic acid	C03242	53486	306
Mead acid	C21938	5312531	306
Eicosadienoic acid	C16525	5282805	308
Eicosenoic acid	C16526	5282768	310
Arachidic acid	C06425	10467	312
Docosahexaenoic acid	C06429	445580	328
Docosapentaenoic acid (n-3)	C16513	5497182	330
Docosapentaenoic acid (n-6)		5282848	330
Docosatetraenoic acid	C16527	5497181	332
Docosatrienoic acid	C16534	5312557	334
Docosadienoic acid	C16533	51090862	336
Docosenoic acid	C08316	10514	338
Docosanoic acid (Behenic acid)	C08281	10479	340
Nervonic acid	C08323	10521	366
Lignoceric acid	C08320	10518	368
Hexacosenoic acid	C17278	5282775	394
Hexacosanoic acid	C21931	10469	396
METABOLITES_END
#END